SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

10796	Companies
233363	Keywords
162043	Articles
124567	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/20/2024 at 11:30, 1 year 10 months ago

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study
Study shows tolebrutinib delays disability progression in non-relapsing secondary progressive MS by 31%; global regulatory submissions in H2 2024. ECTRIMS 2024 data presented

ECTRIMS 2024 Tolebrutinib Disability Progression Secondary Progressive MS Global Regulatory Submissions
BRIEF

published on 09/16/2024 at 18:49, 1 year 10 months ago

Sanofi Reports Share and Voting Rights Data for August 2024

Voting Rights Shares Investor Relations Sanofi August 2024
PRESS RELEASE

published on 09/16/2024 at 18:44, 1 year 10 months ago

Sanofi: Information concerning the total number of voting rights and shares - August 2024
Sanofi discloses total number of voting rights and shares as per French Commercial Code and AMF regulations

Voting Rights French Commercial Code Shares AMF Regulations Sanofi
BRIEF

published on 09/11/2024 at 07:10, 1 year 10 months ago

Dupixent Phase 3 Study Shows Promise for CSU Patients

Sanofi Phase 3 Dupixent CSU Regeneron
PRESS RELEASE

published on 09/11/2024 at 07:05, 1 year 10 months ago

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU. Positive pivotal data support Dupixent as a new targeted therapy for CSU

Phase 3 Study Dupixent CSU Chronic Spontaneous Urticaria Itch And Hives
BRIEF

published on 09/11/2024 at 07:05, 1 year 10 months ago

Dupixent Demonstrates Significant Efficacy in Bullous Pemphigoid

Clinical Trial Sanofi Dupixent Bullous Pemphigoid Disease Remission
PRESS RELEASE

published on 09/11/2024 at 07:00, 1 year 10 months ago

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study
Dupixent achieves significant improvements in disease remission and symptoms in bullous pemphigoid study. Study met primary and key secondary endpoints with beneficial steroid-sparing effect

Dupixent Bullous Pemphigoid Disease Remission Symptoms Steroid-sparing Effect
BRIEF

published on 08/09/2024 at 21:16, 1 year 11 months ago

Sanofi publishes its capital and voting rights figures for July 2024

Share Capital Voting Rights Financial Markets Authority July 2024 Sanofi Actions
PRESS RELEASE

published on 08/09/2024 at 21:11, 1 year 11 months ago

Sanofi: Information concerning the total number of voting rights and shares - July 2024
Sanofi discloses total voting rights and shares as per French Commercial Code and AMF Regulations for July 31, 2024

French Commercial Code Total Voting Rights AMF Regulations Sanofi July 31 2024
BRIEF

published on 08/08/2024 at 07:05, 1 year 11 months ago

Sarclisa Improves Progression-Free Survival for Multiple Myeloma Patients Eligible for Transplant

Clinical Study Sanofi Multiple Myeloma Sarclisa Progression-free Survival

Accesswire

Published on 08/03/2026 at 23:00, 4 hours 34 minutes ago

Viemed Healthcare Announces Second Quarter 2026 Financial Results
Published on 08/01/2026 at 01:20, 3 days 2 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 3 days 2 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 3 days 3 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement
Published on 08/01/2026 at 00:25, 3 days 3 hours ago

BioNxt Solutions Announces Option Grants

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 23:33, 4 hours ago

EQS-Adhoc: Verbio SE: Preliminary EBITDA for FY 2025/2026 exceeds forecast
Published on 08/03/2026 at 23:20, 4 hours 13 minutes ago

DeFi Technologies Announces Shareholder Call to Discuss Q2 2026 Financial Results
Published on 08/03/2026 at 21:39, 5 hours 54 minutes ago

PAUL Tech AG reports net income after tax of EUR 3.2 million for fiscal year 2025 and issues a positive outlook for fiscal year 2026
Published on 08/03/2026 at 19:35, 7 hours 58 minutes ago

Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
Published on 08/03/2026 at 19:01, 8 hours 33 minutes ago

EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026

Les Echos

Published on 08/03/2026 at 18:45, 8 hours 49 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 18:00, 9 hours 34 minutes ago

H1 2026 revenue
Published on 08/03/2026 at 17:45, 9 hours 49 minutes ago

Monthly disclosure of the total number of shares and voting rights - July 2026
Published on 08/03/2026 at 17:45, 9 hours 49 minutes ago

Weekly share buyback
Published on 08/03/2026 at 17:40, 9 hours 54 minutes ago

Eiffage announces the end of exclusive negotiations with Atlas Arteria for the possible acquisition of the Warnow Tunnel concession in Rostock, Germany

View all LES ECHOS COMFI WIRE